Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC

JH Tchaicha, EA Akbay, A Altabef, OR Mikse, E Kikuchi… - Cancer research, 2014 - AACR
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …
被引用次数：45 相关文章

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC

JH Tchaicha, EA Akbay, A Altabef… - Cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non-small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC

JH Tchaicha, EA Akbay, A Altabef… - Cancer …, 2014 - utsouthwestern.elsevierpure.com
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non-small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …
[HTML] nih.gov

[HTML][HTML] Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC

JH Tchaicha, EA Akbay, A Altabef, OR Mikse… - Cancer …, 2014 - ncbi.nlm.nih.gov
Abstract Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-
5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and …

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.

JH Tchaicha, EA Akbay, A Altabef, OR Mikse… - Cancer …, 2014 - europepmc.org
Abstract Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-
5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and …
[PDF] academia.edu

[PDF][PDF] Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

JH Tchaicha, EA Akbay, A Altabef, OR Mikse… - Cancer Res, 2014 - academia.edu
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …
[PDF] researchgate.net

[PDF][PDF] Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

JH Tchaicha, EA Akbay, A Altabef, OR Mikse… - Cancer Res, 2014 - researchgate.net
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …

[引用][C] Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

JH Tchaicha, EA Akbay, A Altabef, OR Mikse… - Cancer …, 2014 - cir.nii.ac.jp
Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to
a Pan-FGFR Inhibitor in a Mouse Model of NSCLC | CiNii Research CiNii 国立情報学研究所 …
[PDF] core.ac.uk

[PDF][PDF] Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

RG Rhee - Cancer Res, 2014 - core.ac.uk
Abstract Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-
5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and …

Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC

JH Tchaicha, E Akbay, A Altabef, OR Mikse… - Cancer …, 2014 - dash.harvard.edu
Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) are present in 4-5% of
patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in …